Bausch Health Companies Earnings Call Transcripts
Fiscal Year 2026
-
Q2 saw record revenue and adjusted EBITDA growth, with all segments contributing and strong cash flow reducing net debt. Guidance for 2026 was raised across all metrics, though H2 faces headwinds from inventory accruals, loss of exclusivity, and Medicaid/340B erosion.
-
Management highlighted sustained growth across key franchises, strong execution in China and Solta, and a focus on maximizing cash flow through 2027. The company is preparing for post-XIFAXAN transition, managing legal risks, and considering options to monetize its BLCO stake.
-
Twelve consecutive quarters of growth were driven by strong Salix and Solta performance, with AI-powered strategies sustaining XIFAXAN's momentum. Liquidity is robust, with plans to monetize B&L shares post-2028, and guidance incorporates regulatory and global risks.
-
The meeting confirmed quorum, introduced ten director nominees, and presented three voting items: director elections, executive compensation, and auditor appointment. All proposals passed by majority vote, and no shareholder questions were received.
-
Revenue and adjusted EBITDA grew double digits year-over-year, led by Salix and Solta, with strong cash flow and reduced net debt. Guidance for 2026 is reaffirmed, including minimal expected tariff impact, and AI-driven initiatives are boosting commercial and R&D productivity.
-
Management emphasized profitable growth, capital structure improvement, and innovation across four business segments. Key growth drivers include Salix, Solta, and international markets, with major pipeline readouts (RED-C, larsucosterol) expected soon.
Fiscal Year 2025
-
Delivered eleventh straight quarter of revenue and adjusted EBITDA growth, with 2025 results exceeding guidance and strong performance across all segments. 2026 guidance calls for continued growth, though 2027 EBITDA is expected to dip due to pricing and exclusivity changes.
-
Management outlined a strategy focused on growth in GI, international, and Solta Medical, with a strong pipeline and operational consistency. XIFAXAN’s exclusivity is under legal review, with key trial data expected early next year. Capital structure flexibility and innovation remain top priorities.
-
Delivered 10th straight quarter of revenue and adjusted EBITDA growth, raising full-year guidance across all key metrics. Strong segment performance led by Salix and Solta, with strategic moves including the DURECT acquisition and Medicaid/340B exit.
-
Reported 5% revenue and 10% adjusted EBITDA growth year-over-year, driven by strong performance in Salix, Solta, EMEA, and Canada. Reaffirmed 2025 guidance and announced the DURECT acquisition to expand the hepatology portfolio. Debt refinancing and capital structure improvements continue.
-
Q1 2025 saw 6% revenue and 14% adjusted EBITDA growth (ex-Bausch + Lomb), driven by strong segment performance and a $7.9B refinancing that extended debt maturities. Full-year revenue and EBITDA guidance were maintained, while cash flow guidance was lowered due to higher interest expense.
Fiscal Year 2024
-
Delivered seventh consecutive quarter of revenue and Adjusted EBITDA growth, with 2024 revenues up 5% and Adjusted EBITDA up 8% year-over-year (excluding Bausch + Lomb). 2025 guidance targets continued growth, while strong cash flow enabled nearly $1 billion in net debt reduction.
-
Delivered sixth consecutive quarter of year-over-year growth in revenue and Adjusted EBITDA, raising full-year guidance across key metrics. All segments showed organic growth, with notable strength in Salix, Solta, and international markets. Litigation and capital allocation remain key focus areas.
-
Q2 2024 marked the fifth consecutive quarter of year-over-year growth in revenue and Adjusted EBITDA, driven by strong performance in Xifaxan, Solta, and international markets. The company maintained its 2024 guidance, continued deleveraging, and advanced its R&D pipeline, while reaffirming the strategic priority of separating Bausch + Lomb.